Septième (7ème) édition de la liste nationale des médicaments essentiels, cinquiême (5ème) édition de la liste nationale des produits pharmaceutiques d'urgence, quatrième (4ème) édition de la liste nationale des réactifs essentiels pour l'analyses de biologie médicale.
La présente é...dition épouse les différents niveaux de laboratoires, aux produits d'urgence, aux médicaments vitaux pour la mère et l'enfant et aux dispositifs utilisés en Odontostomatologie.
more
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
National Tuberculosis Programme and Senior Paediatricians
This guideline was first developed in 2007 but further updated in 2012 and 2016 to ensure the use of the latest evidence-based international recommendations on childhood TB. The guidelines will fill the gaps in a systematic approach to T...B in children and will help to achieve an internationally recommended standard of care at all levels of the health system in Myanmar.
more
This publication is an updated version of the Management of Tuberculosis and HIV Coinfection clinical protocol released in 2007 by the WHO Regional Office for Europe. It is intended for all health care workers involved in preventing, diagnosing, treating and caring for people living with TB and HIV ...in the specific settings of the WHO European Region.
more
Supplement Article
Antiretrovirals to Prevent HIV Infection • CID 2015:60 (Suppl 3) • S159 - S160
Medizinische KlinikIntensivmedizin und Notfallmedizin
https://doi.org/10.1007/s00063-020-00674-3
Solidarity” is an international clinical trial to help find an effective treatment for COVID-19, launched by the World Health Organization and partners.
The Solidarity Trial will compare four treatment options against standard of care, to assess their relative effectiveness against COVID-19. By... enrolling patients in multiple countries, the Solidarity Trial aims to rapidly discover whether any of the drugs slow disease progression or improve survival. Other drugs can be added based on emerging evidence.
Until there is sufficient evidence, WHO cautions against physicians and medical associations recommending or administering these unproven treatments to patients with COVID-19 or people self-medicating with them. WHO is concerned by reports of individuals self-medicating with chloroquine and causing themselves serious harm.
more
La presente publicación describe la literatura científica revisada sobre las intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019. El Ministerio de Salud solicitó la revisión de la evidencia disponible para nueve intervenciones terapéuticas frente a COVID-...19. Este listado contempla 03 intervenciones que no fueron consideradas en la Revisión Rápida de Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 . Serie Revisión Rápida N° 02-2020, correspondiendo a Ivermectina, Tocilizumab y pulsos de corticoides. En vista del rol potencial de cada intervención en el tratamiento de COVID-19, se plantearon dos respuestas PICO a fin de revisar la evidencia disponible respecto a siete potenciales opciones para tratamiento específico y dos fármacos que se han señalado como terapia adyuvante para frenar la respuesta inflamatoria presentada en COVID-19.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19.
more
La presente publicación describe un resumen de la evidencia científica disponible sobre el uso de Cloroquina e hidroxicloroquina, así como su profilaxis y tratamiento para COVID-19.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19